1
|
Kuczyńska J, Nieradko-Iwanicka B. Comparison of the effects of ketoprofen and ketoprofen lysine salt on the Wistar rats' nervous system, kidneys and liver after ethyl alcohol intoxication. Biomed Pharmacother 2023; 161:114456. [PMID: 36870283 DOI: 10.1016/j.biopha.2023.114456] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/05/2023] [Revised: 02/24/2023] [Accepted: 02/26/2023] [Indexed: 03/06/2023] Open
Abstract
Side effects of Ketoprofen and ketoprofen lysine salt (KLS) may be inter alia from the central nervous system, kidneys and liver. After binge drinking people often use ketoprofen, which increases the risk for the occurrence of side effects. The aim of the study was to compere effects of ketoprofen and KLS on the nervous system, kidneys and liver after ethyl alcohol intoxication. There were 6 groups of 6 male rats which received: ethanol; 0.9%NaCl; 0.9%NaCl and ketoprofen; ethanol and ketoprofen; 0.9%NaCl and KLS; ethanol and KLS. On day 2, the motor coordination test on a rotary rod and memory and motor activity test in the Y-maze were performed. Hot plate test was performed on day 6. After euthanasia brains, livers and kidneys were taken to histopathological tests. Motor coordination was significant worse in group 5 vs 1,3, p 0.05. Spontaneous motor activity of group 6 was significant better than that of groups 1,5. Pain tolerance of group 6 was significant worse than that of groups 1,4,5. Liver and kidney mass were significantly lower in group 6 vs group 3,5 and vs group 1,3, respectively. The histopathologic examination of the brains and kidneys revealed normal picture in all groups, without signs of inflammation. In the histopathologic examination of the livers in one animal in group 3 some of the specimens showed perivascular inflammation. After alcohol ketoprofen is a better painkiller than KLS. Spontaneous motor activity is better after KLS after alcohol. Both drugs have a similar effect on the kidneys and liver.
Collapse
Affiliation(s)
- Joanna Kuczyńska
- Department of Hygiene and Epidemiology, Medical University of Lublin, Chodźki 7 Street, 20-093 Lublin, Poland; Doctoral School, Medical University of Lublin, Poland.
| | - Barbara Nieradko-Iwanicka
- Department of Hygiene and Epidemiology, Medical University of Lublin, Chodźki 7 Street, 20-093 Lublin, Poland.
| |
Collapse
|
2
|
Turgut K, Yavuz E, Gülaçtı U, Aydın İ, Sönmez C, Aktaş N, Arslan E. Comparison of Intravenous Paracetamol, Dexketoprofen Trometamol, or Topical Lidocaine Use for Pain Relief in Scorpion Stings: A Placebo-Controlled, Randomized Study. Wilderness Environ Med 2022; 33:379-385. [PMID: 36229383 DOI: 10.1016/j.wem.2022.08.002] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/01/2022] [Revised: 07/31/2022] [Accepted: 08/08/2022] [Indexed: 11/21/2022]
Abstract
INTRODUCTION After a scorpion sting, patients commonly present to hospitals with pain. Our study sought to compare the analgesic efficacy of IV paracetamol, IV dexketoprofen trometamol, topical lidocaine, and placebo in patients reporting pain after presenting with a history of scorpion sting. METHODS This double-blind, randomized, placebo-controlled study was conducted in the emergency department of a tertiary hospital. Adult patients who presented with the complaint of pain after a scorpion sting and did not have systemic findings were randomly assigned to 1 of the following 4 groups: IV paracetamol, IV dexketoprofen trometamol, topical lidocaine, and placebo. The visual analog scale scores were measured at the time of presentation to the emergency department and at 30 and 60 min to determine the pain intensity. RESULTS The study included 106 patients, of whom 30 were in the paracetamol group, 26 in the dexketoprofen trometamol group, 25 in the topical lidocaine group, and 25 in the placebo group. We did not find a different analgesic effect among the groups in the first 30 min (P=0.185). IV paracetamol, dexketoprofen trometamol, and topical lidocaine did not show different analgesic effects in the first 60 min (P>0.05). IV paracetamol and dexketoprofen trometamol were found to provide a more effective analgesia than the placebo at 60 min (P<0.05). The analgesic effects of topical lidocaine and placebo did not differ (P=0.330). CONCLUSIONS IV paracetamol and IV dexketoprofen trometamol provided analgesia in the first 60 min, similar to topical lidocaine but superior to placebo.
Collapse
Affiliation(s)
- Kasım Turgut
- Department of Emergency Medicine, Research and Training Hospital, Adiyaman University, Adiyaman, Turkey
| | - Erdal Yavuz
- Department of Emergency Medicine, Research and Training Hospital, Adiyaman University, Adiyaman, Turkey.
| | - Umut Gülaçtı
- Department of Emergency Medicine, Research and Training Hospital, Adiyaman University, Adiyaman, Turkey
| | - İrfan Aydın
- Department of Emergency Medicine, Research and Training Hospital, Adiyaman University, Adiyaman, Turkey
| | - Cihat Sönmez
- Department of Emergency Medicine, Research and Training Hospital, Adiyaman University, Adiyaman, Turkey
| | - Nurettin Aktaş
- Department of Emergency Medicine, Research and Training Hospital, Adiyaman University, Adiyaman, Turkey
| | - Ebru Arslan
- Department of Emergency Medicine, Research and Training Hospital, Adiyaman University, Adiyaman, Turkey
| |
Collapse
|
3
|
Kuczyńska J, Pawlak A, Nieradko-Iwanicka B. The comparison of dexketoprofen and other painkilling medications (review from 2018 to 2021). Biomed Pharmacother 2022; 149:112819. [PMID: 35299123 DOI: 10.1016/j.biopha.2022.112819] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/22/2022] [Revised: 03/01/2022] [Accepted: 03/09/2022] [Indexed: 11/28/2022] Open
Abstract
Dexketoprofen is an enantiomer of ketoprofen (S+) that belongs to nonsteroidal anti-inflammatory drugs and has analgesic, anti-inflammatory, and antipyretic properties. Dexketoprofen has a stronger effect than ketoprofen, which makes it a readily used preparation. The review aims to find in recent original publications data about dexketoprofen and its comparison with other painkilling medications. The systematic literature review was conducted in November 2021 (2018 onwards). We selected 12 articles from PubMed, Google Scholar, Medline Complete databases. In the last 4 years, there have been many publications that shed a new light on dexketoprofen. The article is a comparative analysis of dexketoprofen's action vs other nonsteroidal anti-inflammatory drugs and the combination of dexketoprofen with tramadol vs paracetamol with tramadol. The findings of the review confirm that dexketoprofen is a very good pain reliever more potent than paracetamol. Dexketoprofen produces similar effects to lidocaine and dexmedetomidine. Complex preparations containing dexketoprofen and tramadol are very effective painkilling tandem and are more effective than tramadol and paracetamol therapy in the treatment of acute pain.
Collapse
Affiliation(s)
- Joanna Kuczyńska
- Chair and Department of Hygiene and Epidemiology, Medical University of Lublin, Chodzki 7 Street, 20-093 Lublin, Poland; Doctoral School, Medical University of Lublin, Poland.
| | - Angelika Pawlak
- Students' Scientific Association at the Chair and Department of Hygiene and Epidemiology, Medical University of Lublin, Chodzki 7 Street, 20-093 Lublin, Poland.
| | - Barbara Nieradko-Iwanicka
- Chair and Department of Hygiene and Epidemiology, Medical University of Lublin, Chodzki 7 Street, 20-093 Lublin, Poland.
| |
Collapse
|
4
|
Zhong J, Hu J, Mao L, Ye G, Qiu K, Zhao Y, Hu S. Efficacy of Intravenous Lidocaine for Pain Relief in the Emergency Department: A Systematic Review and Meta-Analysis. Front Med (Lausanne) 2022; 8:706844. [PMID: 35111766 PMCID: PMC8801430 DOI: 10.3389/fmed.2021.706844] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/08/2021] [Accepted: 12/22/2021] [Indexed: 11/13/2022] Open
Abstract
ObjectiveTo compare the efficacy of intravenous (IV) lidocaine with standard analgesics (NSAIDS, opioids) for pain control due to any cause in the emergency department.MethodsThe electronic databases of PubMed, Embase, ScienceDirect, CENTRAL, and Google Scholar were explored from 1st January 2000 to 30th March 2021 and randomized controlled trials (RCTs) comparing IV lidocaine with a control group of standard analgesics were included.ResultsTwelve RCTs including 1,351 patients were included. The cause of pain included abdominal pain, renal or biliary colic, traumatic pain, radicular low back pain, critical limb ischemia, migraine, tension-type headache, and pain of unknown origin. On pooled analysis, we found no statistically significant difference in pain scores between IV lidocaine and control group at 15 min (MD: −0.24 95% CI: −1.08, 0.61 I2 = 81% p = 0.59), 30 min (MD: −0.24 95% CI: −1.03, 0.55 I2 = 86% p = 0.55), 45 min (MD: 0.31 95% CI: −0.66, 1.29 I2 = 66% p = 0.53), and 60 min (MD: 0.59 95% CI: −0.26, 1.44 I2 = 75% p = 0.18). There was no statistically significant difference in the need for rescue analgesics between the two groups (OR: 1.45 95% CI: 0.82, 2.56 I2 = 41% p = 0.20), but on subgroup analysis, the need for rescue analgesics was significantly higher with IV lidocaine in studies on abdominal pain but not for musculoskeletal pain. On meta-analysis, there was no statistically significant difference in the incidence of side-effects between the two study groups (OR: 1.09 95% CI: 0.59, 2.02 I2 = 48% p = 0.78).ConclusionIV lidocaine can be considered as an alternative analgesic for pain control in the ED. However, its efficacy may not be higher than standard analgesics. Further RCTs with a large sample size are needed to corroborate the current conclusions.
Collapse
Affiliation(s)
- Junfeng Zhong
- Department of Pain Medicine, Shaoxing People's Hospital, Shaoxing, China
| | - Junfeng Hu
- Department of Pain Medicine, Shaoxing People's Hospital, Shaoxing, China
| | - Linling Mao
- Department of Pain Medicine, Shaoxing People's Hospital, Shaoxing, China
| | - Gang Ye
- Department of Pain Medicine, Shaoxing People's Hospital, Shaoxing, China
| | - Kai Qiu
- Department of Pain Medicine, Shaoxing People's Hospital, Shaoxing, China
| | - Yuhong Zhao
- Department of Pain Medicine, Shaoxing People's Hospital, Shaoxing, China
| | - Shuangyan Hu
- Department of Anesthesiology, Shaoxing Peoples's Hospital, Shaoxing, China
- *Correspondence: Shuangyan Hu
| |
Collapse
|
5
|
Liu Y, Yang T, Li J, Xu H, Li S, Xiong L. Breakthroughs on the clinical management of headache and questions that need to be solved. IBRAIN 2021; 7:298-308. [PMID: 37786564 PMCID: PMC10529177 DOI: 10.1002/ibra.12003] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/31/2021] [Revised: 11/01/2021] [Accepted: 11/01/2021] [Indexed: 10/04/2023]
Abstract
Headache is a common refractory disorder among adults, especially in females, which can lower the quality of life in patients and increase medical costs. Nearly 90% of people have been affected by headache disorders during their lifetime. The severe situation of headaches has drawn the attention of researchers in recent years. Although the mechanism of headache has not been fully understood by us, there are many effective preventive drugs and treatments available. This review is aimed to sum up the progress in clinical trials of headaches in the past 5 years.
Collapse
Affiliation(s)
- Yu‐Cong Liu
- School of AnesthesiologyZunyi Medical UniversityZunyiGuizhouChina
| | - Ting‐Ting Yang
- School of AnesthesiologyZunyi Medical UniversityZunyiGuizhouChina
| | - Jing Li
- School of AnesthesiologyZunyi Medical UniversityZunyiGuizhouChina
| | - Hui‐Chan Xu
- School of AnesthesiologyZunyi Medical UniversityZunyiGuizhouChina
| | - Shun‐Lian Li
- School of AnesthesiologyZunyi Medical UniversityZunyiGuizhouChina
| | - Liu‐Lin Xiong
- Department of AnesthesiologyAffiliated Hospital of Zunyi Medical UniversityZunyiGuizhouChina
- Clinical and Health SciencesUniversity of South AustraliaAdelaideSouth AustraliaAustralia
| |
Collapse
|
6
|
Kuczyńska J, Nieradko-Iwanicka B. Future prospects of ketoprofen in improving the safety of the gastric mucosa. Biomed Pharmacother 2021; 139:111608. [DOI: 10.1016/j.biopha.2021.111608] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/01/2021] [Revised: 04/02/2021] [Accepted: 04/12/2021] [Indexed: 12/11/2022] Open
|
7
|
New Studies on Dexketoprofen. POLISH HYPERBARIC RESEARCH 2021. [DOI: 10.2478/phr-2021-0012] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/11/2023] Open
Abstract
Abstract
Introduction. Dexketoprofen(DEX) belongs to nonsteroidal anti-inflammatory drugs (NSAIDs) and has analgesic, anti-inflammatory, and antipyretic properties. DEX is an enantiomer of ketoprofen (S+) and has a stronger effect than ketoprofen. It is highly effective even after the administration of small doses. The therapy with DEX does not cause serious side effects and is additionally tolerated by the body.
Aim. The review aimed to find original scientific publications on DEX in recent years and its therapeutic efficacy, safety, and tolerability.
Method. A systematic review of scientific articles published no earlier than 2015 was carried out. Materials from the PubMed, Google Scholar, and Medline Complete databases were used. The literature review was carried out in November 2021. Among the publications found, 28 scientific articles were selected for analysis.
Results and discussion. Over the recent years, there have been many publications about DEX. Articles describing new data on DEX in the treatment of pain were analyzed, compared with other drugs and mesotherapy, the latest reports of its combination with tramadol and thiocolchicoside were reviewed, and a new slow release form of DEX and new therapeutic applications of this drug were investigated. After analyzing all the studies, it was found that DEX produced similar or more effective analgesia compared to other drugs and reduced the need for emergency medications. In addition, it was noted that using DEX in combination therapy was far better than taking it alone, and was also found to be effective in raising the epileptic threshold. Mesotherapy achieved higher results in the treatment of pain symptoms compared to DEX. The side effects that appeared as a result of the use of DEX therapy were not life-threatening.
Conclusion. The results of the review confirm that DEX is a very good analgesic, which is more potent than paracetamol and diclofenac sodium while having similar effects to dexmedetomidine and lidocaine. DEX in combination with tramadol or thiocolchicoside is more effective than when the two drugs are used alone. Scientists are working on the long-acting DEX and are looking for new applications of the drug in epilepsy and oncology.
Collapse
|